Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors.
Andrea B ApoloRosa NadalDaniel M GirardiScot A NiglioLisa LeyLisa M CordesSeth M SteinbergOlena Sierra OrtizJacqueline CadenaCarlos DiazMarissa MallekNicole N DavarpanahRene CostelloJane B TrepelMin-Jung LeeMaria J MerinoMohammad Hadi BagheriPaul MonkWilliam D FiggJames L GulleyPiyush K AgarwalVladimir ValeraHeather J ChalfinJennifer C JonesHoward StreicherJohn J WrightYangmin M NingHoward L ParnesWilliam L DahutDonald P BottaroPrimo N LaraBiren SaraiyaSumanta Kumar PalMark N SteinAmir MortazaviPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020)
CaboNivo and CaboNivoIpi demonstrated manageable toxicities with durable responses and encouraging survival in patients with mUC and other GU tumors. Multiple phase II and III trials are ongoing for these combinations.